Literature DB >> 7241373

Furosemide disposition in normal and proteinuric rats: urinary drug-protein binding as a determinant of drug excretion.

T P Green, B L Mirkin.   

Abstract

We have demonstrated recently that the binding of furosemide (FSM) to urinary proteins causes a decrease in the diuretic response that is proportional to the degree of proteinuria. Further studies were conducted to determine whether urinary drug-protein interactions also altered the renal excretion of FSM. Rats were treated with puromycin aminonucleoside to produce proteinuria. Renal FSM clearance was directly related to urinary protein excretion rate (r = 0.550, P less than .005), a relationship that was more striking when FSM clearance was normalized to glomerular filtration rate (r = 0.781, P less than .001). This relationship was not explained by changes in serum protein concentration or glomerular filtration rate. In order to understand the mechanism of this relationship, normal and nephrotic rats were studied during experimental conditions designed to alter urinary pH. In normal animals urinary acidification induced by HCl infusion produced a profound decrease in renal FSM clearance compared to animals with the more alkaline urine that followed NaHCO2 or acetazolamide pretreatment. This alteration in renal FSM clearance during urinary acidification was not observed in nephrotic animals, despite comparable changes in urinary pH. The diuretic response to FSM did not differ among the normal animals despite the alteration in renal FSM clearance, indicating that the reduction of renal FSM clearance was due to tubular reabsorption of FSM distal to its site of action. These data suggest that urinary drug protein binding may impair the tubular reabsorption of drugs and thereby enhance their renal clearance.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7241373

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

1.  The influence of moderate hypoalbuminaemia on the renal metabolism and dynamics of furosemide in the rabbit.

Authors:  V Pichette; D Geadah; P du Souich
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

Review 2.  Resistance to loop diuretics. Why it happens and what to do about it.

Authors:  D C Brater
Journal:  Drugs       Date:  1985-11       Impact factor: 9.546

Review 3.  Treatment of Disorders of Sodium Balance in Chronic Kidney Disease.

Authors:  David H Ellison
Journal:  Adv Chronic Kidney Dis       Date:  2017-09       Impact factor: 3.620

Review 4.  Diuretic use in renal disease.

Authors:  Domenic A Sica
Journal:  Nat Rev Nephrol       Date:  2011-12-20       Impact factor: 28.314

5.  Serum and Urine Albumin and Response to Loop Diuretics in Heart Failure.

Authors:  Antonios Charokopos; Matthew Griffin; Veena S Rao; Lesley Inker; Krishna Sury; Jennifer Asher; Jeffrey Turner; Devin Mahoney; Zachary L Cox; F Perry Wilson; Jeffrey M Testani
Journal:  Clin J Am Soc Nephrol       Date:  2019-04-22       Impact factor: 8.237

6.  Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism.

Authors:  M G Lee; W L Chiou
Journal:  J Pharmacokinet Biopharm       Date:  1983-12

7.  Determinants of bumetanide response in the dog: effect of probenecid.

Authors:  D E Smith; H S Lau
Journal:  J Pharmacokinet Biopharm       Date:  1983-02

8.  Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition.

Authors:  S H Kim; Y M Choi; M G Lee
Journal:  J Pharmacokinet Biopharm       Date:  1993-02

9.  Disposition and pharmacodynamics of diuretics and antihypertensive agents in renal disease.

Authors:  B L Mirkin; T P Green; R F O'Dea
Journal:  Eur J Clin Pharmacol       Date:  1980-07       Impact factor: 2.953

10.  Pharmacokinetics and effects of frusemide in patients with the nephrotic syndrome.

Authors:  P A Sjöström; B G Odlind; B A Beermann; B E Karlberg
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.